1-4 of 4
Mark S. Huberman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2277.
https://doi.org/10.1158/1078-0432.CCR-20-0939
Published: 01 May 2020
View article titled, Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Open the PDF for Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas in another window
Journal Articles

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6548–6555.
https://doi.org/10.1158/1078-0432.CCR-18-1541
Published: 13 December 2018
View article titled, EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Open the PDF for EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas in another window
Includes: Supplementary data
Journal Articles

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Daniel B. Costa, Kim-Son H. Nguyen, Byoung C. Cho, Lecia V. Sequist, David M. Jackman, Gregory J. Riely, Beow Y. Yeap, Balázs Halmos, Joo H. Kim, Pasi A. Jänne, Mark S. Huberman, William Pao, Daniel G. Tenen, Susumu Kobayashi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7060–7067.
https://doi.org/10.1158/1078-0432.CCR-08-1455
Published: 03 November 2008
View article titled, Effects of Erlotinib in <em>EGFR</em> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Open the PDF for Effects of Erlotinib in <em>EGFR</em> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib in another window
Journal Articles

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balazs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3908–3914.
https://doi.org/10.1158/1078-0432.CCR-06-0462
Published: 03 July 2006
View article titled, Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
Open the PDF for Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib in another window